Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
The data is delayed by 15 minutes.
ALKS is in the long-term up 172% in 15 years.
Description: Alkermes Public Limited Company, an integrated biopharmaceutical company, develops medicines that enhance patient outcomes. The company offers RISPERDAL CONSTA for schizophrenia and bipolar I disorder; INVEGA SUSTENNA to treat schizophrenia; AMPYRA/FAMPYRA to treat multiple sclerosis; BYDUREON to treat type II diabetes; VIVITROL for alcohol and opioid dependence; TRICOR, LIPANTHYL, LIPIDIL, and SUPRALIP to lower cholesterol; ZANAFLEX for muscle spasticity; AVINZA for moderate to severe pain; EMEND to treat nausea associated with chemotherapy and surgery; and FOCALIN XR and RITALIN LA for attention deficit and hyperactivity disorder. Its products also include MEGACE ES to treat cachexia associated with AIDS; LUVOX CR for obsessive-compulsive disorder; RAPAMUNE to prevent renal transplant rejection; NAPRELAN for mild to moderate pain indications; VERAPAMIL SR, VERELAN, VERELAN PM, VERAPAMIL PM, VERECAPS, UNIVER, and AFEDlTAB CR for hypertension; DILZEM SR, DILZEM XL, DILTELAN, and CARDIZEM CD for hypertension a
|Shares Outstanding||EPS||-1.31||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||5.08%||Sales Growth - Q/Q||-7.96%||P/E||-43.63|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-1.89%||ROE||-2.56%||ROI||-2.04%|
|Current Ratio||8.79||Quick Ratio||8.36||Long Term Debt/Equity||0.39||Debt Ratio||0.08|
|Gross Margin||72.77%||Operating Margin||-15.17%||Net Profit Margin||-5.6%||Dividend Payout Ratio|
|Cash From Financing Activities||17.94 M||Cash From Investing Activities||-31.78 M||Cash From Operating Activities||-13.33 M||Gross Profit||120.95 M|
|Net Profit||-46.11 M||Operating Profit||-52.52 M||Total Assets||1.91 B||Total Current Assets||1.02 B|
|Total Current Liabilities||134.22 M||Total Debt||354.81 M||Total Liabilities||515.68 M||Total Revenue||151.37 M|
|High 52 week||67.26||Low 52 week||33||Last close||34.34||Last change||-0.03%|
|RSI||34.49||Average true range||1.63||Beta||1.3||Volume||502.8 K|
|Simple moving average 20 days||-7.13%||Simple moving average 50 days||-13.72%||Simple moving average 200 days||-25.44%|
|Performance Week||0.73%||Performance Month||-14.21%||Performance Quart||-23.43%||Performance Half||-24.97%|
|Performance Year||-31.53%||Performance Year-to-date||-37.26%||Volatility daily||3.16%||Volatility weekly||7.06%|
|Volatility monthly||14.47%||Volatility yearly||50.11%||Relative Volume||195.73%||Average Volume||806.49 K|
|New High||New Low|
2019-06-18 15:42:13 | Did You Manage To Avoid Alkermes's NASDAQ:ALKS Painful 56% Share Price Drop?
2019-06-18 08:06:55 | See what the IHS Markit Score report has to say about Alkermes Plc.
2019-06-15 08:07:34 | See what the IHS Markit Score report has to say about Alkermes Plc.
2019-06-13 10:26:02 | Alkermes Initiates Monothearpy Expansion Phase of ALKS 4230
2019-06-13 08:06:46 | See what the IHS Markit Score report has to say about Alkermes Plc.
2019-06-11 11:04:05 | Here’s What Hedge Funds Think About Alkermes Plc ALKS
2019-06-11 08:08:20 | See what the IHS Markit Score report has to say about Alkermes Plc.
2019-06-10 08:07:53 | See what the IHS Markit Score report has to say about Alkermes Plc.
2019-06-08 08:12:57 | See what the IHS Markit Score report has to say about Alkermes Plc.
2019-06-06 09:30:01 | CBM vs. ALKS: Which Stock Should Value Investors Buy Now?
2019-06-06 08:08:01 | See what the IHS Markit Score report has to say about Alkermes Plc.
2019-06-04 08:08:27 | See what the IHS Markit Score report has to say about Alkermes Plc.
2019-05-31 09:07:01 | Biogen Reports Interim Phase III Data on Diroximel Fumarate
2019-05-29 10:34:02 | Allergan's AGN Vraylar Gets FDA Nod for Bipolar Depression
2019-05-25 09:31:01 | Why Is Alkermes ALKS Down 21% Since Last Earnings Report?
2019-05-22 11:34:56 | Does Alkermes plc's NASDAQ:ALKS CEO Salary Compare Well With Others?
2019-05-16 09:30:01 | ALXN or ALKS: Which Is the Better Value Stock Right Now?
2019-05-14 16:01:00 | Alkermes to Present at the UBS Global Healthcare Conference
2019-05-07 08:05:51 | See what the IHS Markit Score report has to say about Alkermes Plc.
2019-04-30 08:06:48 | See what the IHS Markit Score report has to say about Alkermes Plc.
2019-04-26 16:27:03 | Edited Transcript of ALKS earnings conference call or presentation 25-Apr-19 12:30pm GMT
2019-04-26 15:58:00 | Alkermes Looks Ahead to Growth
2019-04-26 09:11:00 | Alkermes PLC ALKS Q1 2019 Earnings Call Transcript
2019-04-26 07:26:11 | Alkermes ALKS Reports Narrower-Than-Expected Loss in Q1
2019-04-25 15:47:00 | Biogen Looks to 23 Clinical Programs for Growth
2019-04-25 15:21:00 | Here's Why Shares of Alkermes Sank Today
2019-04-25 09:30:01 | GILD vs. ALKS: Which Stock Is the Better Value Option?
2019-04-25 07:00:00 | Alkermes Plc Reports First Quarter 2019 Financial Results
2019-04-25 06:30:00 | Alkermes Plc to Host Earnings Call
2019-04-24 13:43:27 | Here’s What Hedge Funds Think About Alkermes Plc ALKS
2019-04-19 13:37:20 | Has Alkermes plc NASDAQ:ALKS Got Enough Cash?
2019-04-18 16:00:00 | Alkermes to Host Conference Call to Discuss First Quarter 2019 Financial Results
2019-04-18 10:33:02 | Earnings Preview: Alkermes ALKS Q1 Earnings Expected to Decline
2019-04-10 10:46:02 | Alkermes Reports Positive Data From Schizophrenia Study
2019-04-09 10:51:30 | See what the IHS Markit Score report has to say about Alkermes Plc.
2019-04-09 07:35:29 | Alkermes says long-acting drugs could help schizophrenics stay on medication longer
2019-04-08 17:15:00 | Alkermes Announces Departure of Jim Robinson
2019-04-07 17:04:02 | The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts
2019-04-03 07:00:00 | Alkermes Expands Awards Program With Focus on Advancing Research in Schizophrenia
2019-04-02 11:55:56 | See what the IHS Markit Score report has to say about Alkermes Plc.
2019-04-01 12:38:52 | Drug companies that benefit from the war on opioid addiction